Peripheral indoleamine 2,3-dioxygenase 1 is required for comorbid depression-like behavior but does not contribute to neuropathic pain in mice

Brain, Behavior, and Immunity

Volumn 46, Issue , 2015, Pages 147-153

  Zhou, Wenjun ^a   Dantzer, Robert ^a   Budac, David P ^b   Walker, Adam K ^a   Mao Ying, Qi Liang ^a,c   Lee, Anna W ^b   Heijnen, Cobi J ^a   Kavelaars, Annemieke ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b LUNDBECK RESEARCH USA   (United States)

^c FUDAN UNIVERSITY   (China)

Author keywords

Brain; Depression; Indoleamine 2,3 dioxygenase 1; Interleukin 1; Liver; Neuropathic pain

Indexed keywords

INDOLEAMINE 2,3 DIOXYGENASE; INDOLEAMINE 2,3 DIOXYGENASE 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; KYNURENINE; MESSENGER RNA; TRYPTOPHAN; UNCLASSIFIED DRUG;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; COMORBIDITY; CONTROLLED STUDY; DEPRESSION LIKE BEHAVIOR; FORCED SWIM TEST; GENE DELETION; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIMIT OF DETECTION; LIVER; LOCOMOTION; MALE; MASS SPECTROMETRY; MECHANICAL HYPERALGESIA; MOTOR DYSFUNCTION; MOUSE; MYELITIS; NERVE INJURY; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOCIAL INTERACTION; SPARED NERVE INJURY; TRYPTOPHAN METABOLISM; ANIMAL; ANIMAL BEHAVIOR; BRAIN; COMPLICATION; DEPRESSION; DISEASE MODEL; GENETICS; METABOLISM; MOTOR ACTIVITY; NEURALGIA; PHYSIOLOGY; SPINAL CORD;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DEPRESSION; DISEASE MODELS, ANIMAL; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LIVER; MALE; MICE; MOTOR ACTIVITY; NEURALGIA; SPINAL CORD;

EID: 84928825794     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.01.013     Document Type: Article

References (33)

1. Abrahamsen B., et al. The cell and molecular basis of mechanical, cold, and inflammatory pain. Science 2008, 321:702-705.
2. Alberati-Giani D., et al. Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells. J. Neurochem. 1996, 66:996-1004.
3. Alexander G.M., et al. Plasma amino acids changes in complex regional pain syndrome. Pain Res. Treat. 2013, 742407. 10.1155/2013/742407.
4. Arnow R.A., et al. Comorbid depression, chronic pain, and disability in primary care. Psychosom. Med. 2006, 68:262-268.
5. Bair M.J., et al. Depression and pain comorbidity: a literature review. Arch. Intern. Med. 2003, 163:2433-2445.
6. Chamberlain C.S., et al. Ineterleukin-1 receptor antagonist modulates inflammation and scarring after ligament injury. Connect. Tissue Res. 2014, 55:177-186.
7. Clark A.K., et al. P2X7-dependent release of interleukin-1β and nociception in the spinal cord following lipopolysaccharide. J. Neurosci. 2010, 30:573-582.
8. Corona A.W., et al. Fractalkine receptor (CX3CR1) deficiency sensitizes mice to the behavioral changes induced by lipopolysaccharide. J. Neuroinflam. 2010, 7(93). 10.1186/1742-2094-7-93.
9. Dowlati Y., et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
10. Eijkelkamp N., et al. GRK2: a novel cell specific regulator of severity and duration of inflammatory pain. J. Neurosci. 2010, 30:2138-2149.
11. Guillemin G.J., et al. Expression of the kynurenine pathway enzymes in human microglia and macrophages. Adv. Exp. Med. Biol. 2003, 527:105-112.
12. Guillemin G.J., et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J. Neurochem. 2001, 78:842-853.
13. Ikeda H., Kiritoshi T., Murase K. Contribution of microglia and astrocytes to the central sensitization, inflammatory and neuropathic pain in the juvenile rat. Mol. Pain 2012, 8:43. 10.1186/1744-8069-8-43.
14. Kim H., et al. Brain indoleamine 2,3-dioxygenase contributes to the comorbidity of pain and depression. J. Clin. Invest. 2012, 122:2940-2954.
15. Kita T., et al. Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the l-kynurenine and quinolinic acid pools in brain. J. Neurochem. 2002, 82:258-268.
16. Lawson M.A., et al. Intracerebroventricular administration of lipopolysaccharide induces indoleamine-2,3-dioxygenase-dependent depression-like behaviors. J. Neuroinflam. 2013, 10.1186/1742-2094-10-87.
17. Magni G., et al. Chronic musculoskeletal pain and depressive symptoms in the national health and nutrition examination, I: epidemiologic follow-up study. Pain 1993, 53:163-168.
18. Nguyen N.T., et al. Aryl hydrocarbon receptor and kynurenine: recent advances in autoimmune disease research. Front Immunol. 2014, 5:551. 10.3389/fimmu.2014.00551.
19. Norman G.J., et al. Stress and IL-1beta contribute to the development of depression-like behavior following peripheral nerve injury. Mol. Psychiatry 2010, 15:404-414.
20. Norman G.J., et al. Social interaction prevents the development of depressive-like behavior post nerve injury in mice: a potential role for oxytocin. Psychosomatic Med. 2010, 72:519-526.
21. O'Connor J.C., et al. Lipopolysaccharide-induced depression-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol. Psychiatry 2009, 14:511-522.
22. O'Connor J.C., et al. Induction of IDO by Bacille Calmette-Guérin is responsible for development of murine depression-like behavior. J. Immunol. 2009, 182:3202-3212.
23. Pineda-Farias J.B., et al. The l-kynurenine-probenecid combination reduces neuropathic pain in rats. Eur. J. Pain 2013, 17:1365-1373.
24. Raghavendra V., et al. Complete Freunds adjuvant-induced peripheral inflammation evokes glial activation and proinflammatory cytokine expression in the CNS. Eur. J. Neurosci. 2004, 20:467-473.
25. Raison C.L., et al. CSF concentrations of brain tryptophan and kynurenines during immune stimulation with IFN-alpha: relationship to CNS immune responses and depression. Mol. Psychiatry 2010, 15:393-403.
26. Stockinger B., et al. The aryl hydrocarbon receptor: multitasking in the immune system. Annu. Rev. Immunol. 2014, 32:403-432.
27. Trivedi M.H. The link between depression and physical symptoms. Prim. Care Companion J. Clin. Psychiatry 2004, 6(Suppl. 1):12-16.
28. Vécsei L., et al. Kynurenines in the CNS: recent advances and new questions. Nat. Rev. Drug Discov. 2013, 12:64-82.
29. Von Korff M., et al. An epidemiologic comparison of pain complaints. Pain 1988, 32:173-183.
30. Walker A.K., et al. NMDA receptor blockade by ketamine abrogates lipopolysaccharide-induced depression-like behavior in C57BL/6J mice. Neuropsychopharmacology 2013, 38:1609-1616.
31. Wang H., et al. Balancing GRK2 and Epac1 levels prevents and relieves chronic pain. J. Clin. Invest. 2013, 123:5023-5034.
32. Willemen H.L.D.M., et al. MicroRNA-124 as a novel treatment for persistent hyperalgesia. J. Neuroinflam. 2012, 9:143.
33. Zhou W., et al. Behavioral stress-induced activation of FoxO3a in cerebral cortex of mice. Biol. Psychiatry 2011, 71:583-592.